Lymphatic vessel endothelial hyaluronan receptor 1 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors

Pancreas

Volumn 35, Issue 4, 2007, Pages

  Tomita, Tatsuo ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Lymphatic vessels; LYVE 1; Mouse; Pancreatic islets and pancreatic endocrine tumors

Indexed keywords

CELL RECEPTOR; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; PARAFFIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOCRINE TUMOR; GASTRINOMA; GLUCAGONOMA; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INSULINOMA; PANCREAS ISLET; PRIORITY JOURNAL; SOMATOSTATINOMA; STRUCTURE ACTIVITY RELATION;

CYTOPLASM; DOWN-REGULATION; GASTRINOMA; GLUCAGONOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INSULINOMA; ISLETS OF LANGERHANS; LYMPHATIC VESSELS; PANCREATIC NEOPLASMS; SOMATOSTATINOMA; VESICULAR TRANSPORT PROTEINS;

EID: 37349085404     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318068fcba     Document Type: Article

References (34)

1. Banerji S, Ni J, Wang SW, et al. LYVE-1, a new homologue of the CD 44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
2. Jackson DG, Prevo R, Clasper S, et al. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001;22:317-321.
3. Prevo R, Banerji S, Ferguson JP, et al. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem. 2001;276:19420-19430.
4. Jackson DG. The lymphatics revisited. New perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med. 2003;13:1-7.
5. Stacker SA, Baldwin ME, Acher MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 2002;16:922-934.
6. Carreira CM, Nasser SM, di Tonaso E, et al. LYVE-1 is not restricted to the lymph vessel. Cancer Res. 2001;61:8079-8084.
7. Sipos B, Klapper W, Kruse ML, et al. Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol. 2004;165:1187-1197.
8. Rubbia-Brandt L, Terris B, Giostra E, et al. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res. 2004;10:6919-6928.
9. Nakano T, Nakashima Y, Yonemitau Y, et al. Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol. 2005;36:330-340.
10. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol. 1997;10:47-54.
11. Tomita T. Metallothionein in pancreatic endocrine neoplasms. Mod Pathol. 2000;13:389-395.
12. Tomita T. Amylin in pancreatic islets and pancreatic endocrine neoplasm. Pathol Int. 2003;53:591-595.
13. Catoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357-363.
14. LYVE-1. In: R and D Systems 2006 catalog; 2006; p 564.
15. Tammela T, Saaristo A, Lohela M, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood. 2005;105:4642-4648.
16. Tomita T, Mah K, Cao WG, et al. Cyclic changes in endometrial lymphatics. J Soc Gynecol Invest. 2006;13(suppl 1):81A. "Abstract".
17. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoral lymph vessels in human metastatic breast cancer. J Pathol. 2003;200:195-206.
18. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol. 2004;57:741-751.
19. Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1 positive lymphatic vessels numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004;10:7144-7149.
20. Dadras SS, Paul T, Bertocini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162:1951-1960.
21. Strame O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 2003;9:250-256.
22. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction. J Natl Cancer Inst. 2002;94:417-421.
23. Koukourakis MI, Giatromanolaki A, Sirridis E. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol. 2005;58:202-206.
24. Navas V, O'Morchoe PJ, O'Morchoe CC. Lymphatic system of the rat pancreas. Lymphology. 1995;28:4-20.
25. Kallskog O, Kampf C, Anderson A, et al. Lymphatic vessels in pancreatic islets implanted under renal capsule of rats. Am J Transplant. 2006;6:680-686.
26. Al-Rawi MAA, Mansel RE, Jiang WG. Molecular and cellular mechanisms of lymphangiogenesis. Eur J Surg Oncol. 2005;31:117-121.
27. Tomita T. New markers for pancreatic islets and islet cell tumors. Pathol Int. 2002;52:425-432.
28. Nausia-Arvanitakis S, Tomita T, Doull V, et al. Pancreatic polypeptide in cystic fibrosis. Arch Pathol Lab Med. 1985;109:722-726.
29. Garcia del Torre N, Buley I, Wass JASH, et al. Angiogenesis and lymphangiogenesis in parathyroid proliferative lesions. J Clin Endocrinol Metab. 2004;89:2890-2896.
30. Schmid K, Birner P, Gravenhorst V, et al. Prognostic value of lymphatic and blood vessel invasion in neuroendocrine tumors of the lung. Am J Surg Pathol. 2005;29:324-328.
31. Kahn HJ, Bailey O, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and subset of angiosarcoma. Mod Pathol. 2002;15:434-440.
32. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology. 2005;46:396-402.
33. Wigle JT. Prox-1 function is required for the development of the murine lymphatic system. Cell. 1999;98:769-778.
34. Jussila L, Valtola TA, Partanen P, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58:1599-1604.